Fri 23'rd Feb 2018
Tekla Life Sciences Investors Stock Analysis
Technical stock analysis for Fri 23'rd Feb 2018
|Shorts||0.44% ( 2013-01-15 )|
Tekla Life Sciences Investors lies in the middle of a wide and weak rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 7.62% during the next 3 months and, with 90% probability hold a price between $20.91 and $23.65 at the end of this period.
A buy signal was issued from a pivot bottom point on Thursday February 22, 2018, which indicates further gains until a new top pivot has been found. Tekla Life Sciences Investors has rising volume and follows the last lift in the price. This is considered to be a technical positive sign as volume should follow the price-formation. Higher liquidity also reduces the general risk. Some negative signals were issued as well, and these may have some influence on the near short-term development. Tekla Life Sciences Investors holds a buysignal from the short-term moving average; at the same time, however, a sales signal from the long-term average. Since the longterm average is above the short-term average there is a general sales signal in the stock. On further gains, the stock will meet resistance from the long-term moving average at $20.24. On a fall, the stock will find some support from the short-term average at $19.96. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sales signal and strengthen the general signal.
Relative Strength Index (RSI)
RSI14 is 48 and the stock is currently not being overbought or oversold
Support & Resistance
Tekla Life Sciences Investors finds support from accumulated volume at $19.22. On the upside the stock meets some resistance just above today's level from accumulated volume at $20.44, $20.91 and $21.03.
The stock is about to test the resistance from accumulated volume at $20.44 and this may cause the stock to take a minor break or get into a more sideways move for a few days.
This stock is usually traded at good volume, and with minor daily changes the risk is considered to be low. During the last day, the stock moved $0.40 (2.02%) between high and low. For the last week, the stock has had a daily average volatility of 1.50%.
Our recommended stoploss: $18.89 (-5.83%) (This stock has medium daily movements and this gives medium risk. There is a buy signal from pivot bottom found 1 days ago.)
Very Low Low Medium High Very High
Tekla Life Sciences Investors holds several positive signals, but we still don't find these to be enough for a buy-recommendation. At the current level we recommend to hold or accumulate in this position whilst awaiting for further development. We have upgraded our recommendation for this stock since last evaluation from a Sell Candidate to a Hold/Accumulate.
Trade HQL CFDs with Plus500
Your capital is at risk.
Important: Plus500 doesn't offer signals and it is a CFD service.
Plus500UK Ltd is authorised and regulated by the Financial Conduct Authority (FRN 509909).
Access these features
Auto portfolios gaining up to 30%
Top 5 Candidates in all Lists
Ultimate List Builder